<DOC>
	<DOCNO>NCT00924352</DOCNO>
	<brief_summary>The primary objective Phase I portion study determine maximum tolerate dose ( MTD ) dose limit toxicity ( DLTs ) Phase II portion study evaluate progression free survival ( PFS ) . Secondary objective response rate , clinical benefit rate , overall toxicity .</brief_summary>
	<brief_title>Trial Dasatinib Plus Ixabepilone 2nd 3rd Line Metastatic Breast Cancer</brief_title>
	<detailed_description>In Phase I portion study , patient receive study treatment accord assign dose level . Ixabepilone administer 1 hour Days 1 , 8 , 15 28-day cycle . Dasatinib administer continuously start Day 1 , Cycle 1 daily ( QD ) . Three patient enrol dose level 0 observe dose-limiting toxicity ( DLT ) 1 course treatment . Dose escalation reduction depend number patient experience DLT follow : - If 0 3 patient experience DLT , 3 additional patient enrol next high dose level . - If 1 3 patient experience DLT , 3 additional patient enrol dose level . - If 2 3 3 3 patient experience DLT , 3 patient enrol next low dose unless 6 patient already treat dose . - If ≥2 6 patient experience DLT dose level , MTD consider exceed . At point , 3 patient treat next low dose . - If 1 6 patient experience DLT , dose level escalate 1 level . Maximum-tolerated dose ( MTD ) define dose ≤1 6 patient experience DLT , ≥2 6 patient experience DLT . In Phase II portion study , dasatinib ixabepilone administer MTD determine Phase I. Dasatinib start Day 1 , Cycle 1 administer continuously daily . Ixabepilone administer 1 hour Days 1 , 8 , 15 28-day cycle . Patients treat agent 8 cycle , stable respond patient eligible monotherapy dasatinib investigator 's discretion absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>A patient must meet follow criterion consider eligible inclusion study : 1 . Patient ability understand willingness sign write informed consent include form accord institutional guideline . 2 . Patient histologicallyproven breast cancer . 3 . Patient locally recurrent metastatic disease , measurable non measurable RECIST criterion . 4 . Patient HER2negative disease disease refractory HER2 direct therapy . 5 . Patient female male ≥ 18 year age . 6 . Patient ( ECOG ) performance status ≤ 2 . 7 . Patient must receive least 1 2 prior chemotherapy regimen locally recurrent metastatic disease . Patients may receive neoadjuvant and/or adjuvant chemotherapy . These prior regimen include ixabepilone dasatinib . A line chemotherapy define one agent use continuously discontinuously ( i.e. , allow break chemo holiday ) without addition new agent . Hormonal therapy consider line therapy . 8 . Prior chemotherapy must complete least 3 week prior study treatment start ( 6 week nitrosoureas mitomycin ) , patient must recover associated toxicity ( except alopecia neuropathy grade 1 accord CTCAE , v3.0 classification ) . 9 . Radiation therapy , immunotherapy , biologic therapy , hormonal/endocrine therapy must complete least 2 week prior study treatment start . Any major surgery must complete least 4 week prior study treatment start . 10 . Patient adequate organ , metabolic bone marrow function follow : 1 . Total bilirubin ≤ 1.0 × institutional ULN 2 . AST , ALT ≤ 2.5 × institutional ULN 3 . Serum sodium , potassium , calcium , magnesium , phosphate ≥ institutional LLN . ( Hypokalemia hypomagnesemia must correct prior dasatinib administration . ) 4 . Serum creatinine &lt; 1.5 × institutional ULN 5 . Hematologic function : ANC ≥ 1500/mm3 . Platelet count ≥ 100,000/mm3 . Hemoglobin ≥ 10.0 g/dL 6 . PT PTT &lt; 1.5 x institutional ULN 11 . Ability take oral medication ( dasatinib must swallow whole ) . 12 . Concomitant medication : 1 . Patient agree discontinue St John 's Wort least 5 day prior start dasatinib therapy receive dasatinib therapy . 2 . Patient agree IV bisphosphonates withhold first 8 week dasatinib therapy due risk hypocalcemia . 3 . The use CYP3A4 inducer , inhibitor , substrate ; medication prolong QT interval ; antacid ; H2 blocker proton pump inhibitor ; medication inhibit platelet function anticoagulation avoid dasatinib therapy . These restricted therapy permit caution medically indicate . 13 . Women childbearing potential must negative serum urine pregnancy test prior start study treatment . 14 . Patients reproductive potential must agree use utilize adequate method contraception throughout treatment least 4 week study treatment stop . A patient meet follow criterion consider eligible inclusion study : 1 . Patient prior treatment ixabepilone , dasatinib , . 2 . Patient 2 prior line chemotherapy locally recurrent metastatic breast cancer . A line chemotherapy define one agent use continuously discontinuously ( i.e. , allow break chemo holiday ) without addition new agent . Hormonal therapy consider line therapy . 3 . Patient receive cumulative dose &gt; 360 mg/m2 doxorubicin &gt; 600 mg/m2 epirubicin . 4 . Prior radiation must include ≥ 30 % major bone marrow contain area ( pelvis , lumbar spine ) . 5 . Patients CTC grade 2 great neuropathy ( motor sensory ) study entry . 6 . Patient evidence CNS brain metastasis , unless CNS brain metastasis treat stable &gt; 3 month . 7 . Patient psychiatric illness social situation would limit prohibit compliance study requirement . 8 . Patient inability take oral medication inability absorb oral medication . 9 . Patient invasive cancer one treat study within 3 year exception surgically cure nonmelanoma skin cancer ; situ carcinoma cervix ; situ carcinoma breast . 10 . Patient receive concurrent cancer therapy ( chemotherapy , radiation therapy , immunotherapy , biologic therapy , hormonal therapy cancer ) . 11 . Patient serious medical condition judge Principal Investigator . 12 . Patient concurrent medical condition may increase risk toxicity . 13 . Patient pleural pericardial effusion grade . 14 . Patient cardiac symptom include follow : 1 . Uncontrolled angina , congestive heart failure myocardial infarction within 6 month study entry . 2 . Diagnosed congenital long QT syndrome . 3 . Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) . 4 . Prolonged QTc preentry ECG ( &gt; 450 msec ) . 5 . Hypokalemia hypomagnesemia correct prior dasatinib administration . 15 . Patient history significant bleeding disorder unrelated cancer , include : 1 . Diagnosed congenital bleeding disorder ( e.g. , von Willebrand 's disease ) . 2 . Diagnosed acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) . 3 . Ongoing recent ( ≤ 3 month ) significant GI bleeding . 16 . Patient take follow concomitant medication study entry : . Category I drug generally accept risk cause Torsades de point include ( Patients must discontinue drug 7 day prior start dasatinib . ) : quinidine , procainamide , disopyramide . amiodarone , sotalol , ibutilide , dofetilide . erythromycin , clarithromycin . chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide . cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine . 17 . Patient history allergic reaction attribute compound similar chemical biologic composition ixabepilone dasatinib . Ixabepilone contraindicate patient know , prior , severe ( CTC grade 3 4 ) history hypersensitivity reaction drug formulate Cremophor® EL ( polyoxyethylated castor oil ) . 18 . Patient receive investigational agent therapy within 30 day prior study treatment start . 19 . Patient unwilling unable comply study requirement . 20 . Women : 1. unwilling unable use acceptable method avoid pregnancy entire study period least 4 week cessation study treatment , 2. positive pregnancy test baseline , 3. pregnant breastfeeding . 21 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>